Sector: Health Care
BOSTON SCIENTIFIC CORP · Meeting: April 30, 2026
Directors FOR
10
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Election of Directors
Joined the board in July 2024 (less than 24 months ago), so he is exempt from the TSR trigger under policy; brings relevant CEO and financial expertise with no overboarding or other policy concerns.
BSX's 3-year return of +28% outperforms the IHI (iShares US Medical Devices ETF) benchmark by +27.4 percentage points, well below the 65-percentage-point threshold needed to trigger a concern; Ludwig brings deep medtech governance expertise and no other flags apply.
As CEO and executive director, Mahoney is subject to the same TSR test as other directors; BSX's 3-year return of +28% vs. IHI's +0.6% yields a positive gap of +27.4 percentage points, far below the 65-percentage-point trigger threshold, so no TSR concern arises.
Joined in June 2023 (approximately 33 months ago), which is more than 24 months but less than 3 years; the 3-year TSR trigger does not fire given BSX's strong outperformance of IHI, and her medical and technology expertise is clearly relevant.
Joined in June 2023 (approximately 33 months ago); TSR trigger does not apply given BSX's strong outperformance of IHI, and her deep medtech industry and finance background is directly relevant.
Joined in May 2024 (less than 24 months ago), so she is exempt from the TSR trigger under policy; her healthcare CEO and clinical expertise are well-suited to BSX's business.
Joined in February 2026 (well under 24 months), so she is exempt from the TSR trigger under policy; her CFO-level financial expertise and public company board experience are directly relevant.
Joined in February 2026 (well under 24 months), so he is exempt from the TSR trigger under policy; his global pharmaceutical CEO experience adds relevant strategic oversight capability.
BSX's 3-year return of +28% outperforms IHI (iShares US Medical Devices ETF) by +27.4 percentage points, far below the 65-percentage-point threshold needed to trigger a concern; Wichmann brings strong healthcare CEO and financial expertise.
BSX's 3-year return of +28% outperforms IHI (iShares US Medical Devices ETF) by +27.4 percentage points, well below the 65-percentage-point trigger threshold; Zane brings relevant healthcare and governance experience with no other policy flags.
All ten director nominees receive a FOR vote. BSX's 3-year price return of +28% outperforms the IHI (iShares US Medical Devices ETF) benchmark by +27.4 percentage points, which is well below the 65-percentage-point trigger threshold applicable to companies with strong positive TSR. Directors who joined within the past 24 months (Habiger, Pegus, Smith, Weber) are exempt from the TSR trigger entirely. No overboarding, independence, attendance, or familial-relationship concerns were identified for any nominee.
CEO
Michael F. Mahoney
Total Comp
$23,532,050
Prior Support
N/A
CEO total compensation of $23.5 million is within a reasonable range for the chief executive of a $93 billion large-cap medical device company with a strong 3-year track record. The pay structure is heavily weighted toward variable, performance-based compensation — at least 50% of total pay is in long-term equity and annual bonus tied to measurable financial goals (adjusted net sales, adjusted EPS, adjusted operating income margin) plus a relative total shareholder return program benchmarked against the S&P 500 Health Care Index, meeting the pay-mix quality standard. BSX's 3-year return of +28% significantly outperforms the IHI (iShares US Medical Devices ETF) by +27.4 percentage points, confirming that above-benchmark incentive pay is supported by strong shareholder returns, satisfying the pay-for-performance alignment check.
Auditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$17,995,000
Non-Audit Fees
$1,180,000
Non-audit fees (audit-related fees of $925,000 plus tax fees of $255,000 = $1,180,000) represent approximately 6.6% of audit fees ($17,995,000), well below the 50% threshold that would raise independence concerns. Auditor tenure is not explicitly disclosed in the proxy, so the tenure trigger cannot fire per policy. Ernst & Young is a Big 4 firm fully appropriate for a company of BSX's size and complexity. No material financial restatements were identified.
4 proposals submitted by shareholders
Proposal 5
This is a board-proposed charter amendment that directly responds to a stockholder proposal that received over 95% support at the 2025 annual meeting — one of the clearest possible signals that shareholders want this change. The amendment removes 80% supermajority voting requirements on key governance provisions (director removal, special meeting rules, bylaw amendments) and replaces them with simple majority votes, which is a straightforward pro-shareholder improvement. Supporting this proposal aligns with the policy's guidance to support governance changes that eliminate entrenchment mechanisms and improve shareholder rights.
Proposal 6
Delaware law was changed in 2022 to allow companies to extend to certain officers the same protection from personal liability for honest mistakes that directors have long enjoyed. The proposed amendment is narrowly scoped — it does not protect against breaches of loyalty, bad faith, intentional misconduct, or transactions where an officer personally benefits improperly — and it only applies to direct claims, not derivative suits brought on behalf of the company. Extending this protection helps attract and retain qualified executives and aligns BSX's charter with standard Delaware corporate practice, without meaningfully weakening shareholder protections against misconduct.
Proposal 7
Currently, BSX shareholders have no ability to call a special meeting at all — that right belongs exclusively to the Board chair, president, or a majority of directors. This proposal creates a meaningful new shareholder right by allowing holders of at least 25% of shares (held continuously for one year) to request a special meeting, which is a genuine governance improvement over the current baseline of zero shareholder access. The 25% threshold is the most commonly adopted level among S&P 500 companies that provide this right (approximately 33% of such companies), and the policy guidance supports this type of structural governance improvement. Although a lower threshold (such as 10%) would be even more shareholder-friendly, moving from no right to a 25% right is a substantial improvement worth supporting.
Proposal 8
The board has proactively proposed its own charter amendment (Proposal 7) to grant stockholders holding 25% of shares the right to call a special meeting, directly addressing the core ask of this stockholder proposal. Voting FOR this stockholder proposal would be redundant and could create conflicting or duplicative obligations, since the company's own proposal already remedies the absence of special meeting rights. The right course of action for shareholders who want this governance improvement is to support Proposal 7, which enacts the actual legal change, rather than this advisory stockholder request.
The 2026 Boston Scientific annual meeting features a clean ballot with no significant governance concerns. BSX's strong 3-year total shareholder return of +28% substantially outperforms the IHI (iShares US Medical Devices ETF) benchmark, supporting FOR votes across all ten director nominees and the Say on Pay proposal; three major board-proposed charter amendments meaningfully improve governance by eliminating supermajority requirements, creating new shareholder special meeting rights, and aligning officer liability protections with Delaware law, all warranting support, while the redundant stockholder special meeting proposal should be voted against given the company's own Proposal 7 already delivers the governance improvement.
14 companies disclosed in 2026 proxy filing